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Neuropsychiatric disorders (NPDs) have multiple etiological factors, mainly genetic background, environmental
conditions and immunological factors. The host immune responses play a pivotal role in various physiological and
pathophysiological process. In NPDs, inflammatory immune responses have shown to be involved in diseases
severity and treatment outcome. Inflammatory cytokines and chemokines are involved in various neurobiological
pathways, such as GABAergic signaling and neurotransmitter synthesis. Infectious agents are among the major
amplifier of inflammatory reactions, hence, have an indirect role in the pathogenesis of NPDs. As such, some
infections directly affect the central nervous system (CNS) and alter the genes that involved in neurobiological
pathways and NPDs. Interestingly, the most of infectious agents that involved in NPDs (e.g., Toxoplasma gondii,
cytomegalovirus and herpes simplex virus) is latent (asymptomatic) and co-or-multiple infection of them are
common. Nonetheless, the role of co-or-multiple infection in the pathogenesis of NPDs has not deeply investi-
gated. Evidences indicate that co-or-multiple infection synergically augment the level of inflammatory reactions
and have more severe outcomes than single infection. Hence, it is plausible that co-or-multiple infections can
increase the risk and/or pathogenesis of NPDs. Further understanding about the role of co-or-multiple infections
can offer new insights about the etiology, treatment and prevention of NPDs. Likewise, therapy based on anti-
infective and anti-inflammatory agents could be a promising therapeutic option as an adjuvant for treatment of
NPDs.1. Introduction
Neuropsychiatric disorders (NPDs) are among the most important
morbidity and mortality worldwide [1,2]. According to the estimation,
the global burden of mental illness accounts for 13.0% of
disability-adjusted life-years (DALYs) and 32⋅4% of years lived withli@jums.ac.ir (A. Abdoli).
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is an open access article under tdisability (YLDs) [1]. Several factors, including environmental condi-
tions, genetic background, immune dysregulation and some infectious
agents are known to be involved in the etiopathogenesis of NPDs [3, 4, 5,
6]. In recent years, different investigations have shown the roles of
inflammation in the etiopathogenesis of NPDs and anti-inflammatory
agents as a therapeutic target of NPDs [7]. On the other hand,ovember 2020
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Table 1. A snapshot on microbiology of the major infectious agents that involved in NPDs.
Infectious
agent
Microbiology, transmission, and prevalence Major symptoms
T. gondii ▸Toxoplasma gondii is a protozoan parasite that infects most species of warm-
blooded animals, including humans, and causes the disease toxoplasmosis.
▸Domestic cats are only definitive host and warm-blooded animals and human are
intermediated hosts.
▸Infection usually occurs by eating undercooked contaminated meat, drinking
contaminated water and foods, exposure from infected cat feces, mother-to-child
transmission during pregnancy, receiving an infected organ transplant or infected
blood via transfusion (https://www.cdc.gov/parasites/toxoplasmosis/gen_info/
faqs.html).
▸According to estimation, more than one of the third of the human population
have a history of T. gondii infection [74].
▸Most infected individuals are not aware of it because they have no symptoms at all.
▸Some people who have toxoplasmosis may feel as if they have the “flu” with swollen
lymph glands or muscle aches and pains that may last for a month or more.
▸Severe toxoplasmosis, causing damage to the brain, eyes, or other organs and is more
likely in individuals who have immunocompromising conditions, such as HIV/AIDS,
organ recipient individuals, and patients with malignancies. (https://www.cdc.gov/
parasites/toxoplasmosis/gen_info/faqs.html).
CMV ▸CMV is a common virus for people of all ages with a seroprevalence ranging from
45 to 100% [75].
▸CMV infected individuals may pass the virus in body fluids, such as urine, saliva,
tears, blood, semen, and breast milk. Hence, the infection can spread through
direct contact with the infected body fluids, sexual contact, breast milk,
transplanted organs and blood transfusions (https://www.cdc.gov/cmv/over
view.html).
▸Most immunocompetent individuals do not have symptoms, however, a flu-like
symptoms may be detected in the first time of infection.
▸Severe symptoms and fatal disease may develop in immunocompromised patients,
and newborn babies with congenital CMV infection (https://www.cdc.gov/cmv/over
view.html).
HSV ▸The HSV is categorized into 2 types: HSV-1 and HSV-2. Both HSV-1 and HSV-2
infections are lifelong.
▸HSV-1 is mainly transmitted by oral-to-oral contact to cause oral herpes (known
as “cold sores”), but can also cause genital herpes. An estimated 3.7 billion people
under age 50 (67%) have HSV-1 infection globally.
▸HSV-1 is mainly transmitted by oral-to-oral contact to cause oral herpes infec-
tion, via contact with the HSV-1 virus in sores, saliva, and surfaces in or around the
mouth. However, HSV-1 can also be transmitted to the genital area through oral-
genital contact to cause genital herpes.
▸HSV-2 is a sexually transmitted infection that causes genital herpes. An estimated
491 million people aged 15–49 (13%) worldwide have HSV-2 infection.
▸HSV-2 is mainly transmitted during sex, through contact with genital surfaces,
skin, sores or fluids of someone infected with the virus. HSV-2 can be transmitted
from skin in the genital or anal area that looks normal and is often transmitted in
the absence of symptoms (https://www.who.int/news-room/fact-sheets/detail/h
erpes-simplex-virus).
▸Most oral and genital herpes infections are asymptomatic.
▸Symptoms of herpes include painful blisters or ulcers at the site of infection.
▸ HSV-2 is amongst the most common infections in people living with HIV, occurring
in 60–90% of HIV-infected persons. HSV-2 infection increases the risk of acquiring a
new HIV infection by approximately three-fold. Moreover, people with both HIV and
HSV-2 infection are more likely to spread HIV to others (https://www.who.int/new
s-room/fact-sheets/detail/herpes-simplex-virus).
Rubella ▸Rubella, also known as German measles, is a contagious viral infection that
occurs most often in children and young adults.
▸ Rubella infection in pregnant women may cause fetal death or congenital defects
known as congenital rubella syndrome (CRS).
▸There is no specific treatment for rubella but the disease is preventable by
vaccination.
▸The rubella virus is transmitted by airborne droplets when infected people sneeze
or cough. Humans are the only known host (https://www.who.int/news-room/
fact-sheets/detail/rubella).
▸Rubella virus infection usually causes a mild fever and rash in children and adults,
infection during pregnancy, especially during the first trimester, can result in
miscarriage, fetal death, stillbirth, or infants with congenital malformations, known as
congenital rubella syndrome (CRS).
▸In children, the disease is usually mild, with symptoms including a rash, low fever
(<39 C), nausea and mild conjunctivitis. The rash, which occurs in 50–80% of cases
and lasts 1–3 days. Swollen lymph glands behind the ears and in the neck are the most
characteristic clinical feature.
▸Infected adults, more commonly women, may develop arthritis and painful joints that
usually last from 3–10 days.
Children with CRS can suffer hearing impairments, eye and heart defects and other
lifelong disabilities, including autism, diabetes mellitus and thyroid dysfunction.
▸The highest risk of CRS is in countries where women of childbearing age do not have
immunity to the disease (either through vaccination or from having had rubella)
(https://www.who.int/news-room/fact-sheets/detail/rubella).
EBV ▸EBV, also known as human herpesvirus 4, is a member of the herpes virus family.
It is one of the most common human viruses worldwide.
▸EBV spreads most commonly through bodily fluids, primarily saliva (https://
www.cdc.gov/epstein-barr/about-ebv.html).
▸EBV can cause infectious mononucleosis, also called mono, and other illnesses.
▸Many people become infected with EBV in childhood. EBV infections in children
usually do not cause symptoms. People who get symptoms from EBV infection, usually
teenagers or adults, get better in two to four weeks. However, some people may feel
fatigued for several weeks or even months.
▸The virus becomes latent after infection in some cases, the virus may reactivate. This
does not always cause symptoms, but people with weakened immune systems are more
likely to develop symptoms if EBV reactivates (https://www.cdc.gov/epstein-barr/abo
ut-ebv.html).
Influenza ▸Flu is a contagious respiratory illness caused by influenza viruses that infect the
nose, throat, and sometimes the lungs.
▸Flu viruses spread mainly by tiny droplets made when people with flu cough,
sneeze or talk (https://www.cdc.gov/flu/about/keyfacts.htm).
▸Influenza (flu) can cause mild to severe illness, and at times can lead to death. Flu
usually comes on suddenly.
▸Children are most likely to get sick from flu and that people 65 and older are least
likely to get sick.
▸Symptoms may be included fever, cough, sore throat, runny or stuffy nose, muscle or
body aches, headaches, fatigue. Some people may have vomiting and diarrhea, though
this is more common in children than adults (https://www.cdc.gov/flu/about/keyfact
s.htm).
VZV ▸Varicella-zoster virus (VZV) causes chickenpox and herpes zoster (shingles).
▸Once the illness resolves, the virus remains latent in the dorsal root ganglia. VZV
can reactive later in a person's life and cause a painful, maculopapular rash called
herpes zoster.
▸Chickenpox follows initial exposure to the virus and is typically a relatively mild, self-
limited childhood illness with a characteristic exanthem, but can become disseminated
in immunocompromised children. (https://emedicine.medscape.com/article/231927
-overview)
▸Postherpetic neuralgia (PHN) is the most common complication of herpes zoster.
PHN is pain that persists in the area where the rash once was for more than 90 days
after rash onset. PHN can last for weeks or months, and occasionally, for years.
(continued on next page)
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Table 1 (continued )
Infectious
agent
Microbiology, transmission, and prevalence Major symptoms
▸A person's risk of having PHN after herpes zoster increases with age. Older adults are
more likely to have longer lasting, more severe pain. (https://www.cdc.gov/shingles/h
cp/clinical-overview.html)
BDV ▸BDV first described as a fatal neurologic disease of horses and sheep. Human
infections have been described by serological and molecular methods [76].
▸Human infection has been putative link to mental disorders, but the impact of BDV on
mental-health still remains controversial [77].
Chlamydia
pneumoniae
▸ C. pneumoniae causes respiratory tract infections, such as pneumonia.
▸People spread C. pneumoniae by coughing or sneezing. Other people then breathe
in the bacteria. People can also get sick if they touch something with droplets from
a sick person on it and then touch their mouth or nose. (https://www.cdc.gov/
pneumonia/atypical/cpneumoniae/about/index.html)
▸In general, C. pneumoniae infection is a mild illness that most commonly causes an
upper respiratory tract infection. These upper respiratory tract infections can include a
sore throat or an ear or sinus infection.
▸C. pneumoniae can also cause lower respiratory tract infections like bronchitis and
lung infections like pneumonia. (https://www.cdc.gov/pneumonia/atypical/cpneumo
niae/about/index.html)
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especially maternal infections have been demonstrated in various studies
[8, 9]. Beyond the direct effects on the CNS, infections can augment in-
flammatory pathways, and consequently may have indirect roles in the
etiopathogenesis of NPDs [10, 11, 12]. As well, the most of infectious
agents that involved in NPDs, such as Toxoplasma gondii (T. gondii),
cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein Barr
virus (EBV) is asymptomatic (latent) and co-or-multiple infection of them
are common [13, 14, 15, 16, 17]. Although association of single infection
with NPDs have been investigated in many studies [18, 19, 20, 21], little
is known about the association of co-or-multiple infections and NPDs.
Because co-or-multiple infections have more adverse outcome than single
infection [22, 23, 24, 25, 26, 27, 28, 29, 30], the major question of this
article is: May co-or-multiple infections enhance the risk of NPDs? And,
what is the possible association of co-or-multiple infections with NPDs?
2. Theory/hypothesis
Several indirect links proposed that co-or-multiple infections may be
more involved in the etiopathogenesis of NPDs than single infection: 1)
Some infections are associated with NPDs; 2) infections are associated
with inflammation; 3) inflammation is associated with NPDs; 4) co-or-
multiple infections enhanced a higher level of inflammatory bio-
markers than single infections; 5) co-or-multiple infections have more
severe outcome than single infection; Hence 6) co-or-multiple infections
may have more influence in the etiopathogenesis of NPDs than single
infection.
3. Evidences of the hypothesis
3.1. Inflammation and NPDs
In recent years, psychoneuroimmunology is a hot topic issue in NPDs
and different studies have been focused on the role of immune distur-
bances in the etiology of NPDs [5, 31]. As reviewed elsewhere, inflam-
matory mediators are able to interact with multiple biological pathways
related to NPDs, such as neuroendocrine activity, synaptic plasticity,Figure 1. Alterations of 38 inflammatory mediators in patients with different NPD
major depression disorder (MDD), post-trauma stress disorder (PTSD), sleeping diso
reference [39] (Open access article under a Creative Commons Attribution 4.0 Internatio
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neurocircuits as well as neurotransmitters and monoamine metabolism
[31, 32]. For instance, neuroinflammation activate the kynurenine
pathway that can modulate the N-methyl-D-aspartate (NMDA) receptor
and diminish serotonin production, which consequently is involved in
several NPDs, such as depressive disorders [8]. Inflammatory cytokines
IL-6 and TNF-α increase blood-brain barrier (BBB) permeability, and
blocking of them decreases stress-induced BBB opening [33, 34]. The
result of a recent meta-analysis [12] demonstrated a significant increase
in the levels of IL-17, IL-23, IL-6, TNF-α, soluble IL-2 receptor (sIL-2R),
and IL-1 receptor antagonist (IL-1RA) in acutely ill patients with major
depressive disorder (MDD), schizophrenia, and bipolar mania compared
with controls (P < 0.01). Indeed, a significant increase in the levels of
IL-1β and sIL-2R was detected in patients with chronic schizophrenia and
bipolar disorder [12]. Recent researches have shown that macrophage
migration inhibitory factor (MIF) plays a protective role in the devel-
opment of MDD by upregulating the PI3k/Akt/mTOR pathway and
production of inflammatory cytokines IL-1β and TNFα [35, 36, 37]. On
the other hand, in-vitro, in-vivo, and ex-vivo preclinical data, as well as
data from Alzheimer' s disease patients have shown that MIF is increased
during the course of the disease and that therapeutic targeting of MIF
could beneficial effects on the Alzheimer' s disease course [38].
In an excellent article, Yuan et al. [39] performed an umbrella review
of the meta-analyses regarding alterations of 38 inflammation-related
factors in major NPDs. This study summarized the changes of different
cytokines, chemokines, and growth factors in NPDs (Figure 1). Func-
tionally, cytokines and chemokine are divided into proinflammatory and
anti-inflammatory subsets. Abnormal levels of both pro-and anti-in-
flammatory cytokines and chemokine were detected in several NPDs
(Figure 1) [39, 40, 41].
3.2. Autoimmunity and NPDs
The association between autoimmune disorders with NPDs is another
evidence that link between inflammation and NPDs [42, 43, 44]. So,
higher co-morbidity of some autoimmune diseases and NPDs have been
reported from the epidemiological investigations [44, 45, 46]. In a recent
meta-analysis, Siegmann et al. [46] showed that patients withs. schizophrenia (SCZ), bipolar disorder (BD), autism spectrum disorder (ASD),
rder (SD), obsessive–compulsive disorder (OCD) and suicide. Reproduced from
nal License).
Figure 2. Association of single infections with NPDs. The related references are inserted in each box. * Meta-analysis. [79], [80], [81], [82], [83], [84], [85], [86],
[87], [88], [89], [90], [91], [92], [93], [94], [95], [96], [97], [98], [99], [100], [101].
Figure 3. Association of infectious agents with NPDs (based on Figure 2).
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(OR ¼ 3.56) and anxiety disorders (OR ¼ 2.32). Depression and anxiety
disorders are increased in patients with multiple sclerosis (MS) as well
[47]. In a cohort study among 5084 MS patients, the OR of depression
and anxiety disorders was 1.4 and 1.23 in the prediagnostic period and
the post-diagnostic period, respectively [48]. Rossi et al. [48] found that
depression and anxiety disorders significantly increase inflammatory
cytokines TNF-α, IL1-β, and IL-2 in the CSF samples of MS patients in the
relapsing-remitting stage of the disease [49]. TH17 cells which has a
highly inflammatory properties plays a critical pathogenic role in several
autoimmune diseases [31]. Among the psoriasis patients, anti-IL-17A
therapy resulted in remission of depression in about 40% of the pa-
tients with severe depression [50]. Depressive disorders are not only
common in patients with diabetes [51, 52], but also increase risk of
mortality among these patients (HR ¼ 1.46) [53]. Psychiatric
co-morbidity is also common in patients with other autoimmune disor-
ders, such as inflammatory bowel disease (IBD) [54, 55], Systemic lupus
erythematosus (SLE) [56] and psoriasis [57].
3.3. Anti-inflammatory treatment for NPDs
Anti-inflammatory agents can be used as an adjuvant in combination
with anti-psychotic drugs [58]. The results of different meta-analysis
revealed a diminished level of depressive symptoms after
anti-inflammatory treatment [59]. Indeed, nonsteroidal
anti-inflammatory drugs significantly improved the positive and negative
symptoms of schizophrenia patients [60]. In contrast, Quereda and col-
leagues [61] showed that treatment with Efavirenz and α-interferon in
patients with hepatitis C virus (HCV) and HIV co-infection were partially
led to mood disorders. On the other hand, it has been suggested that an
imbalanced production of cytokines may be involved in the pathogenesis4
and maintenance of NPDs. Taken together, cumulative evidences suggest
the beneficial role of anti-inflammatory treatment as an adjuvant in
treatment of NPDs.
3.4. Antipsychotic therapy modulates inflammatory biomarkers of NPDs
Another evidence that is shown the association of inflammation and
NPDs is the effects of antipsychotic therapy on levels of inflammatory
biomarkers. While clinical and experimental evidences reveal that the
major antipsychotic agents, including lithium, haloperidol, valproate
acid, perazine, clomipramine, fluoxetine and the selective serotonin re-
uptake inhibitors (SSRIs) led to modulation of inflammatory biomarkers
[58, 62, 63]. For instance, the SSRIs decreased peripheral levels of IL-1β,
IL-6, TNF-α and IL-10 [64]. In vitro studies also revealed that inflamma-
tory cytokines IL-1β, TNF-α, and Nuclear factor kappa B (NF-κB) pro-
duction were significantly impeded after exposure to haloperidol [65,
66]. A recent meta-analysis demonstrated that clomipramine and fluox-
etine decrease inflammatory cytokines IL-6, TNF-α, and IFN-γ, whilst
venlafaxine and mirtazapine augment their levels [63].
3.5. Association of latent infections with NPDs
Inflammation is induced by multiple stimulating factors, including
infectious agents [67]. Hence, infections act as an inflammation amplifier
which consequently involves in the etiopathogenesis of NPDs. Till now, a
number of researches demonstrated a positive correlation of different
NPDs with several infectious agents (Table 1), including T. gondii, CMV,
HSV, EBV, rubella, measles, influenza, Borna disease virus (BDV), vari-
cella zoster virus (VZV) [13, 14, 19, 68], and Chlamydia [18, 20] infec-
tion (Figures 2 and 3). Beyond the direct effects of infections on the
central nervous system (CNS), infections affect the immune system that
leads to product inflammatory mediators, such as immune cells and cy-
tokines. These mediators can pass through the blood-brain barrier (BBB)
and generate neuroinflammation [8]. As such, maternal infections in
pregnant women can increase risk of NPDs in the offspring in later life
[14, 17, 69, 70, 71, 72]. On the other hand, depression increased the risk
of infections among women with coronary artery bypass grafting
compared to non-depressed women [73]. Despite the positive correla-
tions between infections and NPDs, limited information is available
about the role of co-or multiple-infections in the etiopathogenesis of
NPDs.
Figure 4. A hypothetical scheme on the possible role of single infection or co-or-multiple infections in the pathogenesis of NPDs. (The figure designed by BioRender
online software).
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the diseases
Quite a few studies have demonstrated that co-or-multiple infections
synergically enhance severity of the diseases. For example, viral co-
infection has several virological and immunological consequences, such
as enhanced virus replication and persistence, altered disease intensity
and altered immunological responses [24]. In the “Spanish flu”
pandemic, 95% of the mortality was attributed to co-infection with
bacterial pneumonia as well [26]. Co-infection of Streptococcus pneumo-
niae with influenza virus promotes inflammatory responses with a strong
IL-17A response that led to enhanced S. pneumoniae disease intensity in
the nasopharynx of infected animals [103]. In vitro study in the human
monocytic cell lines revealed that co-exposure of influenza virus with
Staphylococcus aureus toxins enhanced pro-inflammatory cytokines, such
as TNF-α, IL-1β, and IL-6 [23]. HIV and hepatitis C virus co-infection
promote hepatocellular injury that is linked to elevation of certain in-
flammatory cytokines [104]. In the HIV-infected patients, co-infection
with human herpesvirus 8 (HHV-8) was associated with a persistent
inflammation and immune activation [25]. Previous studies showed that
maternal infection with ToRCH (toxoplasmosis, rubella, CMV and HSV)
co-infection was associated with increased risk of abortion in pregnant
women than their single infection [27]. As such, some studies indicated
that co-infections synergically enhance the level of inflammatory medi-
ators. In this regard, Souza et al. [30] reported that chronic infection with5
T. gondii exacerbates secondary polymicrobial sepsis in an experimental
mouse model and in a human survey. The results revealed that chronic
T. gondii infection suppresses anti-inflammatory T helper (TH)-2 cells and
simultaneously intensifies local and systemic inflammatory TH1 cells and
their inflammatory cytokines, such as IFN-γ and nitric oxide (NO) [30].
These phenomena were resulted in reduced diastolic and systolic blood
pressures after induction of sepsis and led to a severe outcome than un-
infected T. gondii mice with sepsis [30]. A clinical study was also per-
formed by the same group of the researchers [30] regarding the
correlation of T. gondii seropositivity with inflammatory biomarkers in
patients with sepsis. They found that the sepsis severity was positively
correlated with increased IFN-γ levels in T. gondii seropositive patients
compare with T. gondii seronegative septic patients [30]. Hence, accu-
mulating evidence reveals that co-or-multiple infections have more se-
vere outcomes than single infection [22].
3.7. Possible role of co-or-multiple infections in increased risk of NPDs
In a large-scale study among Danish individuals with various psy-
chiatric disorders, Burgdorf and colleagues [78] found a significant as-
sociation between T. gondii and schizophrenia, and between CMV and
attempting or committing suicide, neurotic, stress-related and somato-
form disorders, and mood disorders. Nevertheless, T. gondii and CMV
co-infection did not influence the overall findings [78]. Although, the
levels of inflammatory markers were not reported in this study [78].
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co-infection of Mycoplasma ssp., Chlamydia pneumoniae, and Human
Herpes Virus-6 were higher in patients with ASD than the control group.
Some studies have shown that patients with HCV and HIV co-infection
may be at higher risk for depressive disorders than single infection
[105, 106, 107]. Aibibula and colleagues [105] demonstrated that HIV
patients with depressive symptoms had 1.32 times higher risk of HIV
viremia. As such, in HIV-HCV co-infected patients, occurrence of
depressive symptoms were a risk factor for persistent HIV viremia [105].
To our knowledge, there are not any immunological analyses regarding
the influences of co-or-multiple infections in the etiopathogenesis of
NPDs until now. Hence, it seems that co-or-multiple infections is a
neglected topic in the area of NPDs (Figure 4).
4. Conclusion and future directions
Asmentioned, various studies have shown the role of single infections
in the etiopathogenesis of NPDs, but, the role of co-infections have not
deeply investigated. Torrey and Yolken [6] mentioned that the role of
genetic background in the etiology of schizophrenia may have been
overestimated and an increased attention to gene-environmental in-
teractions can accelerate research development on this disease.
Furthermore, interaction of infectious agents with microbiota composi-
tion can produce a better clinical picture of NPDs [6]. The idea of in-
fectious cause NPDs may open new opportunities for treatment of NPDs
with some antibiotics, antiviral or antiprotozoal agents. As well, in-
vestigations on the role co-or-multiple infections can provide new insides
into the pivotal role of infectious in the etiopathogenesis of NPDs rather
than other etiological factors (e.g., genetic background). Further under-
standing about the influences of co-or-multiple on NPDs can provide new
insights about the etiology, treatment, and prevention of NPDs.
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